A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
Completed
Grünenthal GmbH
Phase 3
2006-11-01
The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at
doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients
with at least a 3-month history of low back pain, or pain caused by knee or hip
osteoarthritis.
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3
2006-11-01
The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at
doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients
with at least a 3-month history of low back pain, or pain caused by knee or hip
osteoarthritis.
A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery
Completed
Grünenthal GmbH
Phase 3
2006-10-01
The purpose of this study is to evaluate in patients who are eligible for elective primary
total or partial joint replacement of the hip or knee due to chronic osteoarthritis the
efficacy (level of pain control) of CG5503 over 5 and 10 days compared with placebo, and to
assess the safety and tolerability of multiple doses of CG5503 IR patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
